Hepatitis at home: ambulatory management of severe immune checkpoint inhibitor-related hepatitis

QJM 2026

View at publisher
Authors: Tim Cooksley, Jamie Mj Weaver, Safwaan Adam, Tomasso Bosetti, Thomas Knight, Daniel S Lasserson, R G Lee, Paul C. Lorigan
DOI: 10.1093/qjmed/hcag130
Cited by: 1
References: 17

Abstract

BACKGROUND: Liver toxicity is common in patients treated with immune checkpoint inhibitor (ICI) therapy. Most guidelines advocate for the admission of patients with grade 3/4 ICI mediated hepatitis. Ambulatory emergency care forms a fundamental part of the strategy of trying to ensure safe and sustainable acute care services. METHODS: An ambulatory pathway for ICI mediated hepatitis (CTCAE grade 3/4) was commenced in March 2023. Patients with ICI mediated hepatitis with normal synthetic liver function (bilirubin

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Drug-Induced Hepatotoxicity and Protection Hepatitis C virus research

Publication details

Journal / source
QJM
Publisher
Oxford University Press (OUP)
Publication date
17 May 2026
Language
EN